*Supplementary Materials*

# Evidence for Enhanced Exosome Production in Aromatase Inhibitor-Resistant Breast Cancer Cells

**Giuseppina Augimeri [1,†], Giusi La Camera [1,†], Luca Gelsomino [1], Cinzia Giordano [1,2], Salvatore Panza [1], Diego Sisci [1], Catia Morelli [1], Balázs Győrffy [3,4], Daniela Bonofiglio [1,2], Sebastiano Andò [1,2,‡], Ines Barone [1,*,‡] and Stefania Catalano [1,2,*,‡]**

[1] Department of Pharmacy, Health and Nutritional Sciences, Via P Bucci, University of Calabria, 87036 Arcavacata di Rende (CS), Italy; giusy.augimeri@gmail.com (G.A.); giusylacamera93@gmail.com (G.L.C.); luca.gelsomino@unical.it (L.G.); cinzia.giordano@unical.it (C.G.); sasapanza@libero.it (S.P.); dsisci@unical.it (D.S.); catia.morelli@unical.it (C.M.); daniela.bonofiglio@unical.it (D.B.)

[2] Centro Sanitario, Via P Bucci, University of Calabria, 87036 Arcavacata di Rende (CS), Italy

[3] Bioinformatics and 2nd Department of Pediatrics, Semmelweis University, 1094 Budapest, Hungary; zsalab2@yahoo.com (B.G.)

[4] TTK Cancer Biomarker Research Group, 1117 Budapest, Hungary

* Correspondence: ines.barone@unical.it (I.B.); stefania.catalano@unical.it (S.C.); Tel.: +39-0984-496216 (I.B.); +39-0984-496207 (S.C.)

† These authors contributed equally to this work.

‡ Joint senior author.




**Figure S1.** Evaluation of apoptosis in MCF-7 and MCF-7 LTED cells. (**a**) Terminal deoxynucleotidyk transferase-mediated dUTP nick end labeling (TUNEL) staining in MCF-7 and LTED cells in serum-free medium for 48h. DAPI was used for nuclear staining; (**b**) Immunoblot analysis of PARP and cleaved-PARP protein levels from total MCF-7 and LTED cellular extracts. β-Actin was used as a control for equal loading and transfer. The histograms represent the mean ± SD of three separate experiments in which band intensities were evaluated in terms of optical density arbitrary units (OD) and expressed as fold over MCF-7 cells. n.s., nonsignificant.

**Table S1.** Oligonucleotide primers used in this study.

| Gene Symbol | Gene Name | Primer Sequences |
|---|---|---|
| *RAB3D* | Member RAS oncogene family RAB3D | For 5′- TCAAGACCGTCTACCGCCAT -3′<br>Rev 5′- CTTGATTTGCGTGGCCCAGTC -3′ |
| *RAB5A* | Member RAS oncogene family RAB5A | For 5′- CTAGTCGAGGCGCAACAAGA -3′<br>Rev 5′- GGGTTAGAAAAGCAGCCCCA -3′ |
| *RAB5B* | Member RAS oncogene family RAB5B | For 5′- CGGAGCCCCAGGAGTGTT -3′<br>Rev 5′- CACTGCAGATTCTCCCAGCA -3′ |
| *RAB6A* | Member RAS oncogene family RAB6A | For 5′- GCCCGTGCAAATGTATCTGTG -3′<br>Rev 5′- GACCCGCAGTATCCCACAG -3′ |
| *RAB7A* | Member RAS oncogene family RAB7A | For 5′- CCTCGAAAACAGACAAGTGGC -3′<br>Rev 5′- ATTCCGTGCAATCGTCTGGA -3′ |
| *RAB11A* | Member RAS oncogene family RAB11A | For 5′- ACGTCATCTCAGGGCAGTTC-3′<br>Rev 5′- GAGAAACAATGCGGTAAATCTCTGT -3′ |
| *RAB12* | Member RAS oncogene family RAB12 | For 5′- TCATCATTATCGGCTCCCGC -3′<br>Rev 5′- TTGAAGTCAACACCCACGGT -3′ |
| *RAB14* | Member RAS oncogene family RAB14 | For 5′- ACCATGGCAACTGCACCATA -3′<br>Rev 5′- TCCTACTCCCATGTCCCCAAT -3′ |
| *RAB18* | Member RAS oncogene family RAB18 | For 5′- ACTTGCAGCAACAATAGGTGT -3′<br>Rev 5′- TAACACCCTGTGCACCTCTA -3′ |
| *RAB21A* | Member RAS oncogene family RAB21A | For 5′- AACGACAAGCACATCACCAC -3′<br>Rev 5′- TCTTGACCTGCCGTATCCCAT -3′ |
| *RAB22A* | Member RAS oncogene family RAB22A | For 5′- TCAACCCAACAATAGGGGCA -3′<br>Rev 5′- ATTATAGCTGCAGCCGACCC -3′ |
| *RAB23* | Member RAS oncogene family RAB23 | For 5′- TCCCGGGTTGTGCCTTACT -3′<br>Rev 5′- TCTTCCCTCTCAAATCGCTGGG-3′ |
| *RAB24* | Member RAS oncogene family RAB24 | For 5′- GAGATCGGGGTTTGCCTCCC -3′<br>Rev 5′- CGGCCCCGATGGTGTTCT -3′ |
| *RAB27B* | Member RAS oncogene family RAB27B | For 5′- ATAAGTAGCTGTCCCCGTGC -3′<br>Rev 5′- GATGGTCTTGGTCGGTCAGC -3′ |
| *RAB32* | Member RAS oncogene family RAB32 | For 5′- CATCGCGGGGCAGGAG -3′<br>Rev 5′- AGAGGACAGCAGGGATAGGG -3′ |